ALL patients who received Aucatzyl immunotherapy, made from their own T cells, experienced complete remission within three ...

If it weren't for a stem cell transplant — less than half a cup of blood from a stranger's umbilical cord — four-year-old ...

The market’s momentum is fueled by a concerted effort towards the development of innovative treatments for hematologic malignancies. Advances in drug discovery, coupled with regulatory approvals for ...

Scientists at Flinders University in Australia have made a discovery that could change how we understand cancer’s origins.

Phase 3 study on previously untreated chronic lymphocytic leukemia showed sustained PFS with venetoclax-obinutuzumab.

According to a new market research report, 'Minimal Residual Disease Testing Market Size, Share, Forecast, & Trends Analysis ...

Targeted therapy revolutionized cancer treatment, with gene fusions leading the way when the FDA approved imatinib in 2001 to ...

Ascentage Pharma, a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies.

National Cancer Awareness Day serves as a poignant reminder of the significant burden of cancer in India, including blood cancers like leukemia, lymphoma, and myeloma. Every year over 1 lakh people in ...

A new approach helps examine the proportion of cancerous and healthy stem cells in patients with chronic myeloid leukemia and how this influences treatment outcomes.

A recent study by researchers at the Garvan Institute of Medical Research has uncovered a connection between gene variants ...

New data will showcase significantly increased and sustained minimal residual disease (MRD) negativity rates, reinforcing the potential of CARVYKTI to transform outcomes in refractory multiple myeloma ...